Agios Pharma (AGIO) Releases Initial AG-120 Data; Oppenheimer Reiterates Perform
Oppenheimer reiterated a Perform rating on Agios Pharma (NASDAQ: AGIO) following initial data from an ongoing phase I trial of AG-120. AG-120 was generally well tolerated in advanced solid tumors including glioma, IHCC and chondrosarcoma, with no dose-limiting toxicities (DLTs) observed based on the safety analysis of 62 treated patients as of the data cut off date.
Analyst Ling Wang commented, "AGIO reported initial data from an ongoing phase I trial of AG-120 in advanced IDH1- mutant solid tumors yesterday at the EORTC-NCI-AACR International Conference in Boston, MA. As of cut off day September 3, 2015, 62 patients have been treated and 25 patients remain on treatment. AG-120 showed good tolerability, favorable PK, inhibition of 2-HG and preliminary signals of clinical activity. Novel measurement/ approach might be needed to better gauge the treatment impact of AG-120 in solid tumors, especially in glioma. Four expansion cohorts (25 patients each) are currently enrolling patients with low grade glioma, second-line cholangiocarcinoma, high grade chondrosarcoma, and other solid tumors. AGIO also plans to initiate a randomized phase II study of AG-120 in cholangiocarcinoma in 2016."
For an analyst ratings summary and ratings history on Agios Pharma click here. For more ratings news on Agios Pharma click here.
Shares of Agios Pharma closed at $75.83 yesterday.